HIGHBuilt-in & outside partyProduct / Revenue mix
XDEMVY
“10-K Item 1A: 'a single product approved for commercial sale ... We have one product, XDEMVY®'”
TARS · Concentration risk · 10-K extracted
Tarsus Pharmaceuticals (TARS) concentration risks
Updated
The most significant concentration Tarsus Pharmaceuticals discloses is XDEMVY, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Tarsus Pharmaceuticals’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
contract manufacturer in Europe
“10-K Item 1A: 'XDEMVY is currently being filled and finished by a reputable contract manufacturer in Europe'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-06-24The company's disclosed concentration profile reflects the characteristics of a single-product commercial-stage specialty pharmaceutical company: a high-share product dependency and a high-share manufacturing dependency, with both exposures centered on the same asset. The company has one product approved for commercial sale — XDEMVY — a high-share, mixed-character exposure. The mixed character reflects both the structural fact that the company has deliberately concentrated its commercial launch around this single ophthalmic product, and the dependency dimension that all near-term revenue, gross profit, and commercial execution risk flows through XDEMVY's prescription volume, reimbursement status, and competitive positioning. The manufacturing side is equally concentrated: XDEMVY is currently being filled and finished by a reputable contract manufacturer in Europe, a high-share dependency. The fill-finish process is a critical late-stage manufacturing step where disruption — whether from capacity constraints, quality events, or regulatory inspection findings at the European facility — could directly affect product supply continuity. A single contract manufacturer handling fill-finish for the company's only commercial product provides no backup redundancy at this stage. The two exposures are tightly coupled: the entire commercial franchise depends on XDEMVY's supply chain functioning without interruption at a single European facility. No customer, geographic, or other supplier concentration is disclosed in the source claims. On balance, the concentration profile is that of an early commercial-stage company at the peak of single-product, single-manufacturer dependency — a structure that is common at this stage but which leaves no operational fallback if either the product or the manufacturing relationship encounters a sustained disruption.
For the engine’s reasoning on TARS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| TARS● | Tarsus Pharmaceuticals, Inc. | 2 | 0 | 0 | 2 |
| ACLX | Arcellx, Inc. | 1 | 1 | 0 | 2 |
| AGIO | Agios Pharmaceuticals, Inc. | 1 | 0 | 0 | 1 |
| ALMS | Alumis Inc. | 1 | 0 | 0 | 1 |
| ADMA | ADMA Biologics Inc | 0 | 1 | 0 | 1 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.